|Earnings per share||29,375.00 KRW|
|Capitalization (mn)||2,285,670 KRW|
|Net income (mn)||1,938,750 KRW|
|Samsung Biologics dividend|
|Samsung Biologics Price to book Value|
|Samsung Biologics Price to Cash-Flow|
|Samsung Biologics Return on Equity|
|Samsung Biologics Financial analysis|
Samsung Biologics is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Samsung Biologics headquarters are in Korea, where the firm is listed.
At the time of this analysis, Samsung Biologics stocks were trading at a price of 164,500.00 KRW after climbing a 2.20% last month.
Based on the following chart, where Price Earnings Ratio is shown, Samsung Biologics has P/E of 5.60, lower than the amount offered by both companies from Korea and Pharmaceuticals and Biotechnology subsector. This low Price to earnings, might be a sing of a company undervalued or that the market expects a reduction in their earnings.Samsung Biologics financial data could confirm which is the explanation for such a low P/E ratio.
Samsung Card. Korea. Financials.Samsung Electro-Mech. Korea. Industrials.Samsung Electronics. Korea. Consumer Goods.Samsung Eng. Korea. Industrials.Samsung F & M Ins. Korea. Financials.Samsung Fine Chem. Korea. Basic Materials.
Samsonite Internatio. Hong-Kong. Consumer Goods.Sampo Oyi. Finland. Financials.Salvatore Ferragamo. Italy. Consumer Goods.Salesforce.com. USA. Technology.Saipem. Italy. Oil and Gas.Sainsbury (J). UK. Consumer Services.
All rights reserved
Part of Enciclopedia Financiera Group
Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.